MCID: CLS010
MIFTS: 42

Cluster Headache

Categories: Eye diseases, Genetic diseases, Neuronal diseases, Rare diseases

Aliases & Classifications for Cluster Headache

MalaCards integrated aliases for Cluster Headache:

Name: Cluster Headache 20 36 54 70

Classifications:



External Ids:

KEGG 36 H01588
ICD10 32 G44.0
UMLS 70 C0009088

Summaries for Cluster Headache

GARD : 20 Cluster headaches are a form of headache notable for their extreme pain and their pattern of occurring in "clusters", usually at the same time(s) of the day for several weeks. The headaches are accompanied by autonomic symptoms, and some people experience restlessness and agitation. A cluster headache begins with severe pain strictly on one side of the head, often behind or around one eye. In some people, it may be preceded by a migraine-like "aura." The pain usually peaks over the next 5 to 10 minutes, and then continues at that intensity for up to three hours before going away. Typical attacks may strike up to eight times a day and are relatively short-lived. On average, a cluster period lasts 6 to 12 weeks. Autonomic symptoms may include: conjunctival injection (bloodshot eyes), swelling under or around the eye, excessive tearing of the eyes, drooping of the eyelid, runny nose and/or nasal congestion, and forehead and facial sweating. These symptoms generally occur only during the pain attack and are on the same side as the headache pain. Cluster headaches usually begin between the ages of 20 and 50, although they can start at any age. Males are more commonly affected than females. Treatment can be divided into acute therapy aimed at stopping symptoms once they have started and preventive therapy aimed at preventing recurrent attacks during the cluster period.

MalaCards based summary : Cluster Headache is related to headache and migraine with aura, and has symptoms including headache and recurrent paroxysmal headache. An important gene associated with Cluster Headache is HCRTR2 (Hypocretin Receptor 2), and among its related pathways/superpathways are Peptide ligand-binding receptors and Neuroscience. The drugs Methylprednisolone and Prednisolone have been mentioned in the context of this disorder. Affiliated tissues include eye, pituitary and hypothalamus.

KEGG : 36 Cluster headache (CH) is the commonest of the trigeminal autonomic cephalalgias (TAC) characterized by attacks of severe, strictly unilateral pain, which is orbital, supraorbital, temporal, or in any combination of these sites, with duration of pain attacks of 15 to 180 min. The pain of CH is associated with ipsilateral conjunctival injection, lacrimation, nasal congestion, rhinorrhea, forehead and facial sweating, miosis, ptosis and/or eyelid edema, and/or restlessness or agitation. Headaches often recur at the same time each day during the cluster period, which can last for weeks to months. CH occurs more commonly in male patients (2.5:1 to 4.3:1 male to female) with an average age of onset in the third or fourth decade. The pathophysiology of CH is not fully understood, but may include a genetic component. Treatment focuses on avoiding triggers and includes abortive therapies, prophylaxis during the cluster period, and long-term treatment in patients with chronic CH. Evidence supports the use of supplemental oxygen, sumatriptan, and zolmitriptan for acute treatment of episodic CH. Verapamil is used to treat chronic CH. More invasive treatments, including nerve stimulation and surgery, may be helpful in refractory cases.

Wikipedia : 73 Cluster headache (CH) is a neurological disorder characterized by recurrent severe headaches on one side... more...

Related Diseases for Cluster Headache

Diseases in the Cluster Headache family:

Cluster Headache, Familial

Diseases related to Cluster Headache via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 214)
# Related Disease Score Top Affiliating Genes
1 headache 32.3 HCRTR2 CALCA CACNA1A
2 migraine with aura 30.4 VIP CALCA CACNA1A
3 migraine with or without aura 1 30.4 VIP PNOC HCRTR2 CALCA CACNA1A
4 familial hemiplegic migraine 30.1 CALCA CACNA1A
5 sleep disorder 29.8 HCRTR2 CLOCK
6 paine syndrome 29.7 PNOC CALCA
7 drug dependence 29.5 PNOC ADH4
8 disease of mental health 27.3 VIP PNOC HCRTR2 GNB3 CLOCK CALCA
9 cluster headache, familial 11.5
10 paroxysmal hemicrania 11.3
11 hemicrania continua 10.6
12 trigeminal neuralgia 10.5
13 ptosis 10.5
14 migraine without aura 10.5
15 horner's syndrome 10.5
16 ifap syndrome 2 10.4
17 autonomic dysfunction 10.4
18 sleep apnea 10.4
19 trigeminal autonomic cephalalgia 10.4
20 carotid artery dissection 10.3
21 head injury 10.3
22 myositis 10.3
23 meningioma, familial 10.3
24 intracranial meningioma 10.3
25 secretory meningioma 10.3
26 lymphoplasmacyte-rich meningioma 10.3
27 orbital plasma cell granuloma 10.3
28 angina pectoris 10.2
29 arteriovenous malformation 10.2
30 peptic ulcer disease 10.2
31 chronic pain 10.2
32 rare headache 10.2
33 anisocoria 10.1
34 kearns-sayre syndrome 10.1
35 tolosa-hunt syndrome 10.1
36 cerebrovascular disease 10.1
37 paresthesia 10.1
38 familial hypocalciuric hypercalcemia 10.1 CALCA ADH4
39 leprosy 2 10.1 VIP CALCA
40 endocrine pancreas disease 10.1 VIP CALCA
41 pancreatic cholera 10.1 VIP CALCA
42 vasomotor rhinitis 10.1 VIP CALCA
43 autonomic nervous system benign neoplasm 10.1 VIP CALCA
44 peripheral nervous system benign neoplasm 10.1 VIP CALCA
45 vipoma 10.1 VIP CALCA
46 somatostatinoma 10.1 VIP CALCA
47 hemifacial spasm, familial 10.0
48 anxiety 10.0
49 major depressive disorder 10.0
50 major affective disorder 8 10.0

Graphical network of the top 20 diseases related to Cluster Headache:



Diseases related to Cluster Headache

Symptoms & Phenotypes for Cluster Headache

UMLS symptoms related to Cluster Headache:


headache; recurrent paroxysmal headache

Drugs & Therapeutics for Cluster Headache

Drugs for Cluster Headache (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 109)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Methylprednisolone Approved, Vet_approved Phase 4 83-43-2 6741
2
Prednisolone Approved, Vet_approved Phase 4 50-24-8 5755
3
Prednisolone acetate Approved, Vet_approved Phase 4 52-21-1
4
Prednisolone phosphate Approved, Vet_approved Phase 4 302-25-0
5
Methylprednisolone hemisuccinate Approved Phase 4 2921-57-5
6
Magnesium Sulfate Approved, Investigational, Vet_approved Phase 4 7487-88-9 24083
7
Ketamine Approved, Vet_approved Phase 4 6740-88-1 3821
8
Hydroxyzine Approved Phase 4 68-88-2 3658
9
Topiramate Approved Phase 4 97240-79-4 5284627
10
Prednisolone hemisuccinate Experimental Phase 4 2920-86-7
11 Oxazolidinones Phase 4
12 Anti-Infective Agents Phase 4
13 Methylprednisolone Acetate Phase 4
14 Neuroprotective Agents Phase 4
15 Protective Agents Phase 4
16 Anesthetics, Dissociative Phase 4
17 Anesthetics, General Phase 4
18 Anesthetics, Intravenous Phase 4
19 Excitatory Amino Acid Antagonists Phase 4
20 Tocolytic Agents Phase 4
21 Anticonvulsants Phase 4
22 Hypoglycemic Agents Phase 4
23
Sodium oxybate Approved Phase 3 502-85-2 5360545
24
Sumatriptan Approved, Investigational Phase 3 103628-46-2 5358
25
Acetylcholine Approved, Investigational Phase 3 51-84-3 187
26
Zolmitriptan Approved, Investigational Phase 2, Phase 3 139264-17-8 441240 60857
27
Vitamin D Approved, Nutraceutical, Vet_approved Phase 3 1406-16-2
28
Cortivazol Investigational Phase 2, Phase 3 1110-40-3
29 Neurotransmitter Agents Phase 3
30 Vasoconstrictor Agents Phase 3
31 abobotulinumtoxinA Phase 3
32 Cholinergic Agents Phase 3
33 Botulinum Toxins, Type A Phase 3
34 Botulinum Toxins Phase 3
35 Serotonin Receptor Agonists Phase 2, Phase 3
36 Serotonin 5-HT1 Receptor Agonists Phase 2, Phase 3
37 Pharmaceutical Solutions Phase 3
38 Trace Elements Phase 3
39 Nutrients Phase 3
40 Micronutrients Phase 3
41 Vitamins Phase 3
42 Calciferol Phase 3
43
Serotonin Investigational, Nutraceutical Phase 2, Phase 3 50-67-9 5202
44
Angiotensin II Approved, Investigational Phase 2 68521-88-0, 4474-91-3, 11128-99-7 172198
45
Candesartan cilexetil Approved Phase 2 145040-37-5 2540
46
Diphenhydramine Approved, Investigational Phase 2 147-24-0, 58-73-1 3100
47
Histamine Approved, Investigational Phase 2 51-45-6, 75614-87-8 774
48
Promethazine Approved, Investigational Phase 2 60-87-7 4927
49
Cocaine Approved, Illicit Phase 2 50-36-2 5760 446220
50
Verapamil Approved Phase 2 52-53-9 2520

Interventional clinical trials:

(show top 50) (show all 81)
# Name Status NCT ID Phase Drugs
1 4mg StatDose Imitrex for Acute Treatment of Cluster Headache Unknown status NCT00399243 Phase 4 Sumatriptan 4mg Statdose injection
2 Efficacy and Safety of Zolmitriptan by Sublingual Administration in the Treatment of Cluster Headache: A Multi-center Randomized Cross-controlled Trial Unknown status NCT03377257 Phase 4 zolmitriptan by sublingual administration;zolmitriptan by oral
3 GON-injection for a Sooner and Better Treatment of Cluster Headache: a Double-blind Randomized Controlled Trial Recruiting NCT04014634 Phase 4 Methylprednisolone
4 Evaluation of the Efficacy of a Single Infusion of Ketamine Combined With Magnesium Sulfate to Treat Refractory Chronic Cluster Headache Not yet recruiting NCT04814381 Phase 4 Ketamine + Magnesium sulfate (drug combination)
5 Atrioventricular Block and Cluster Headache Not yet recruiting NCT04406259 Phase 4 Verapamil
6 A Single-Center, Randomized, Double-Blind, Placebo Controlled Trial Examining the Safety and Efficacy of Topiramate in the Treatment of Subjects With Episodic or Chronic Cluster Headache. Terminated NCT00203190 Phase 4 Topiramate
7 Safety and Efficacy of Sodium Oxybate in the Prophylaxis of Headache and Sleep Disturbances in Patients With Chronic and Episodic Cluster Headache Unknown status NCT02637648 Phase 3 Sodium Oxybate;Placebo
8 A Double Blind Randomized Controlled Trial of Greater Occipital Nerve Infiltration in Cluster Headache Completed NCT00804895 Phase 2, Phase 3 ALTIM, cortivazol injections;PROAMP, subcutaneous serum physiological saline;Verapamil
9 A Phase 3b Multicenter, Single-Arm, Open-Label Safety Study of LY2951742 (Galcanezumab) in Patients With Episodic or Chronic Cluster Headache Completed NCT02797951 Phase 3 Galcanezumab
10 Anodal Transcranial Direct Stimulation (tDCS) of the Anterior Cingulate Gyrus for the Treatment of Chronic Cluster Headache: a Pilot Trial. Completed NCT02462395 Phase 2, Phase 3
11 A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study of : Galcanezumab (LY2951742) With a Long-Term Open-Label Extension in Patients With Chronic Cluster Headache Completed NCT02438826 Phase 3 Galcanezumab 300 mg;Placebo
12 Occipital Nerve Stimulation in Medically Intractable Chronic Cluster Headache Completed NCT01151631 Phase 3
13 A Phase III, Double-Blind, Randomized, Placebo-Controlled, Parallel-Group, Multicenter Evaluation of Civamide (Zucapsaicin) Nasal Solution in the Treatment of Episodic Cluster Headache Completed NCT00033839 Phase 3 Civamide (Zucapsaicin)
14 A Phase III, Double-Blind, Randomized, Placebo-Controlled, Parallel Group, Multicenter Evaluation of Civamide (Zucapsaicin) Nasal Solution in the Treatment of Episodic Cluster Headache Completed NCT00069082 Phase 3 Civamide (Zucapsaicin);Sodium Chloride
15 A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study of LY2951742 in Patients With Episodic Cluster Headache Completed NCT02397473 Phase 3 Galcanezumab;Placebo
16 Imigran STATdose - Japan Clinical Experience Study for Self-injection Completed NCT00356603 Phase 3 Sumatriptan Succinate
17 Interventional, Randomized, Double-blind, Parallel-group, Placebo-controlled Delayed-start Study to Evaluate the Efficacy and Safety of Eptinezumab in Patients With Episodic Cluster Headache Recruiting NCT04688775 Phase 3 Eptinezumab;Placebo
18 Botulinum Toxin Type A Blockade of the Sphenopalatine Ganglion in Treatment-refractory Chronic Cluster Headache Recruiting NCT03944876 Phase 3 Botulinum toxin type A;placebo
19 Randomized, Double-Blind, Multi-Center, Parallel-Group Comparison of the Efficacy and Safety of the C213 (Zolmitriptan Microneedle System) to Placebo for the Acute Treatment of Cluster Headaches Active, not recruiting NCT04066023 Phase 2, Phase 3 C213 Microneedle System;Placebo
20 A Phase III, Double-Blind, Randomized, Vehicle-Controlled, Parallel-Group, Multicenter Evaluation of Civamide Nasal Solution 0.01% in the Prevention of Cluster Headaches During an Episodic Cluster Headache Period Not yet recruiting NCT01341548 Phase 3 Civamide nasal solution 0.01%
21 High Dose Vitamin D Plus Multivitamin in the Prevention of Cluster Headache: a Randomized, Double-blind, Placebo Controlled Trial. Not yet recruiting NCT04570475 Phase 3 Vitamin D;multivitamin;Placebo
22 A Multicenter, Randomized, Double-Blind, Double-Dummy, Placebo-Controlled, Parallel-Group Study Comparing the Efficacy and Safety of 2 Dose Regimens (Intravenous/Subcutaneous and Subcutaneous) of TEV-48125 Versus Placebo for the Prevention of Epidosic Cluster Headache Terminated NCT02945046 Phase 3 Fremanezumab;Placebo
23 A Multicenter, Randomized, Double-Blind, Double-Dummy, Placebo-Controlled, Parallel-Group Study Comparing the Efficacy and Safety of 2 Dose Regimens (Intravenous/Subcutaneous and Subcutaneous) of TEV-48125 Versus Placebo for the Prevention of Chronic Cluster Headache Terminated NCT02964338 Phase 3 Fremanezumab;Placebo
24 A Multicenter, Double-Blind, Double-Dummy Study to Explore the Long-Term Safety and Efficacy of TEV-48125 for the Prevention of Cluster Headache Terminated NCT03107052 Phase 3 Fremanezumab
25 A Randomized, Multicenter Study for the Prevention and Acute Treatment of Chronic Cluster Headache Using Gammacore, Versus Standard of Care. Completed NCT01701245 Phase 2
26 Proof of Concept Study for Evaluation of the Effect of Ketamine Intranasal Spray in Treatment of Chronic Cluster Headache Completed NCT04179266 Phase 1, Phase 2 Ketamine
27 Prophylactic Treatment of Episodic Cluster Headache With an Angiotensin II Receptor Blocker (Candesartan Cilexetil); a Randomized, Placebo Controlled Parallel Study Completed NCT00184587 Phase 2 candesartan cilexetil;placebo
28 Endoscopic Block of the Sphenopalatine Ganglion With Botulinum Toxin in Intractable Cluster Headache - Safety Issues Completed NCT02019017 Phase 1, Phase 2 Botulinum Toxin Type A 25 IU;Botulinum Toxin Type A 50 IU
29 Botulinum Toxin Type A Block of the Otic Ganglion in Chronic Cluster Headache: Safety Issues Completed NCT03066635 Phase 1, Phase 2 Botulinum Toxin Type A 25 IU;Botulinum Toxin Type A 12.5 IU
30 Safety and Efficacy of Lysergic Acid Diethylamide (LSD) as Treatment for Cluster Headache: a Randomized, Double-blind, Placebo-controlled Phase II Study Recruiting NCT03781128 Phase 2 Lysergic Acid Diethylamide;Placebo
31 Prophylactic Effects of Psilocybin on Chronic Cluster Headache: an Open-label Clinical Trial and Neuroimaging Study Recruiting NCT04280055 Phase 1, Phase 2 Psilocybin
32 Psilocybin-facilitated Treatment for Cocaine Use: A Pilot Study Recruiting NCT02037126 Phase 2 Psilocybin;Diphenhydramine
33 A Multicenter, Placebo-Controlled, Single Dose Study in Acute Episodic and Chronic Cluster Headache to Evaluate the Safety and Efficacy of SOM230 Subcutaneous (s.c.) Terminated NCT02619617 Phase 2 SOM230;Placebo
34 An Open Label, Pilot Study Evaluating the Efficacy and Safety of the Use of Nasal Carbon Dioxide for the Treatment of Episodic Cluster Headache Terminated NCT02381795 Phase 2 Nasal Carbon Dioxide
35 A Randomized, Placebo-Controlled, Double-Blind, Parallel-Group, Phase 2 Study to Evaluate the Safety and Efficacy of R-Verapamil in the Prophylaxis of Episodic Cluster Headache Terminated NCT02209155 Phase 2 R-verapamil 75 mg tablet;Placebo
36 Safety and Efficacy of Psilocybin for the Treatment of Headache Disorders Recruiting NCT02981173 Phase 1 0.143 mg/kg Psilocybin or 10 mg Psilocybin;0.0143 mg/kg Psilocybin or 1 mg Psilocybin;Placebo
37 The Pain Biomarker Study: Changes in Circulating Pain Signalling Molecules With Activation of Pain Receptors Active, not recruiting NCT03511846 Phase 1 Oral capsaicin;Topical capsaicin;Intranasal capsaicin;Low Flow Oxygen;High Flow Oxygen
38 A Pilot Study of Demand Valve Oxygen Inhalation Therapy for Cluster Headache Terminated NCT01298921 Phase 1 Oxygen;Oxygen
39 Intra-arterial Sphenopalatine Ganglion Block for Patients With Refractory Headache Withdrawn NCT04353505 Phase 1 Ketorolac;Dexamethasone
40 CGRP's Cluster Headache Inducing Abilities in Cluster Headache Patients Unknown status NCT02466334 Calcitonin-Gene Related Peptide;Placebo
41 Pathway CH S&E Registry: Data Collection on the ATI Neurostimulation System: SPG Stimulation for Cluster Headache - ATI Neurostimulation System is Branded Internationally as Pulsante™ Microstimulator System Unknown status NCT02440776
42 The Effect of PACAP-38 Infusion in Inducing Headache in Patients With Cluster Headache Unknown status NCT03814226
43 Cluster Headache (CH), Addictions and Vascular Function Unknown status NCT02640105
44 Effectiveness of Physiotherapy Program in Patients With Cluster Headache Unknown status NCT02460003
45 Study of the Cerebral Metabolism in Patients With Refractory Chronic Cluster Headache Treated by Occipital Nerve Stimulation Unknown status NCT02081482
46 Sphenopalatine Ganglion Stimulation for the Treatment of Chronic Cluster Headache Unknown status NCT02168764
47 A Randomized Placebo Controlled Study of Baclofen in the Treatment of Muscle Cramps in Patients With Cirrhosis Unknown status NCT02221570 Baclofen
48 Evaluation of Efficacity and Safety of Deep Brain Stimulation (DBS) in Chronic and Treatment-Resistant Cluster Headache(CH) Completed NCT00662935
49 Sleep in Cluster Headache: Sleep Parameters in- and Outside a Cluster Bout Completed NCT03439722
50 A Randomized, Multicentre, Double-blind, Parallel, Sham-controlled Study of GammaCore®, a Non-invasive Neurostimulator Device for the Acute Relief of Episodic and Chronic Cluster Headache. Completed NCT01958125

Search NIH Clinical Center for Cluster Headache

Inferred drug relations via UMLS 70 / NDF-RT 51 :


Cyproheptadine
Cyproheptadine hydrochloride
CYPROHEPTADINE HYDROCHLORIDE MONOHYDRATE
Dihydroergotamine
ergoloid mesylates, USP
Ergotamine
Oxygen
Sumatriptan
Sumatriptan Succinate

Genetic Tests for Cluster Headache

Anatomical Context for Cluster Headache

MalaCards organs/tissues related to Cluster Headache:

40
Eye, Pituitary, Hypothalamus, Lung, Brain, Heart, Spinal Cord

Publications for Cluster Headache

Articles related to Cluster Headache:

(show top 50) (show all 2946)
# Title Authors PMID Year
1
Calcitonin gene-related peptide in blood: is it increased in the external jugular vein during migraine and cluster headache? A review. 61 54
19330286 2009
2
Haplotype analysis confirms the association between the HCRTR2 gene and cluster headache. 61 54
18399985 2008
3
Investigation of neuromuscular transmission in some rare types of migraine. 61 54
17919307 2007
4
Association between migraine and the G1246A polymorphism in the hypocretin receptor 2 gene. 54 61
17883525 2007
5
CGRP-receptor antagonism in migraine treatment. 54 61
17691979 2007
6
Association between the G1246A polymorphism of the hypocretin receptor 2 gene and cluster headache: a meta-analysis. 61 54
17563843 2007
7
The G1246A polymorphism in the hypocretin receptor 2 gene is not associated with treatment response in cluster headache. 54 61
17376114 2007
8
Serotonin receptor ligands: treatments of acute migraine and cluster headache. 61 54
17087122 2007
9
Cluster headache is associated with the G1246A polymorphism in the hypocretin receptor 2 gene. 54 61
16554494 2006
10
Neurobiology in primary headaches. 61 54
15914251 2005
11
New targets in the acute treatment of headache. 61 54
15891413 2005
12
Clinical data on the CGRP antagonist BIBN4096BS for treatment of migraine attacks. 54 61
15867953 2005
13
Calcitonin gene-related peptide antagonists as treatments of migraine and other primary headaches. 54 61
16392873 2005
14
A polymorphism of the hypocretin receptor 2 gene is associated with cluster headache. 61 54
15477554 2004
15
Blockade of CGRP receptors in the intracranial vasculature: a new target in the treatment of headache. 54 61
15265049 2004
16
Circulating nociceptin levels during the cluster headache period. 54 61
15030536 2004
17
New therapeutic target in primary headaches - blocking theCGRP receptor. 54 61
12783573 2003
18
Calcitonin gene-related peptide (CGRP) in cerebrovascular disease. 61 54
12805934 2002
19
No involvement of the calcium channel gene (CACNA1A) in a family with cluster headache. 61 54
11843863 2001
20
No involvement of the calcium channel gene (CACNA1A) in a family with cluster headache. 61 54
11843867 2001
21
CACNA1A gene polymorphisms in cluster headache. 61 54
11843866 2001
22
[Both neurogenic and vascular causes of primary headache]. 54 61
11680150 2001
23
Sensory nerves in man and their role in primary headaches. 54 61
11595008 2001
24
Pathophysiology of primary headaches. 61 54
11252141 2001
25
Plasma levels of calcitonin gene-related peptide in chronic tension-type headache. 61 54
11087777 2000
26
A pathophysiological view of primary headaches. 54 61
11200801 2000
27
A possible role for saliva as a diagnostic fluid in patients with chronic pain. 54 61
9662753 1998
28
Responsiveness of the trigeminovascular system to nitroglycerine in cluster headache patients. 61 54
9117375 1997
29
Increase in plasma calcitonin gene-related peptide from the extracerebral circulation during nitroglycerin-induced cluster headache attack. 54 61
7540279 1995
30
Neuropeptides in the cerebral circulation: relevance to headache. 54 61
7585922 1995
31
Neuropeptides in migraine and cluster headache. 61 54
7828188 1994
32
Nostril capsaicin application as a model of trigeminal primary sensory neuronal activation. 61 54
7520365 1994
33
Pain localization in cluster headache patients: Onset, peak, and radiation. 61
33523462 2021
34
Secondary headache attributed to exposure to or overuse of a substance. 61
32819151 2021
35
Clinical features of cluster headache without cranial autonomic symptoms: results from a prospective multicentre study. 61
33767287 2021
36
Cluster headache pathophysiology - insights from current and emerging treatments. 61
33782592 2021
37
Machine phenotyping of cluster headache and its response to verapamil. 61
33230532 2021
38
Olfactory dysfunction in patients with cluster headache. 61
33713191 2021
39
Peripheral Nerve Stimulation in Pain Management: A Systematic Review. 61
33740342 2021
40
Melatonin (MEL) and its use in neurological diseases and insomnia: Recommendations of the French Medical and Research Sleep Society (SFRMS). 61
32921425 2021
41
The Role of Galcanezumab in Migraine Prevention: Existing Data and Future Directions. 61
33803190 2021
42
Headaches during pregnancy. 61
32838992 2021
43
Updates on management of headache in women and transgender women. 61
33741810 2021
44
"You will eat shoe polish if you think it would help"-Familiar and lesser-known themes identified from mixed-methods analysis of a cluster headache survey. 61
33502769 2021
45
Systematic literature review and Bayesian network meta-analysis of episodic cluster headache drugs. 61
33629333 2021
46
A retrospective observation on 105 patients with chronic cluster headache receiving indomethacin. 61
33547540 2021
47
Occipital Nerve Stimulation for Pain Modulation in Drug-Resistant Chronic Cluster Headache. 61
33668570 2021
48
Comprehensive clinical phenotyping of nitroglycerin infusion induced cluster headache attacks. 61
33615843 2021
49
Drug profile: galcanezumab for prevention of cluster headache. 61
33206562 2021
50
Recently available and emerging therapeutic strategies for the acute and prophylactic management of cluster headache: a systematic review and expert opinion. 61
33243037 2021

Variations for Cluster Headache

Expression for Cluster Headache

Search GEO for disease gene expression data for Cluster Headache.

Pathways for Cluster Headache

GO Terms for Cluster Headache

Cellular components related to Cluster Headache according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 neuron projection GO:0043005 9.13 VIP GNB3 CALCA
2 neuronal cell body GO:0043025 8.8 PNOC CALCA CACNA1A

Biological processes related to Cluster Headache according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 signal transduction GO:0007165 9.8 VIP PNOC HCRTR2 GNB3 CLOCK
2 chemical synaptic transmission GO:0007268 9.5 PNOC HCRTR2 CACNA1A
3 regulation of insulin secretion GO:0050796 9.48 CLOCK CACNA1A
4 regulation of blood pressure GO:0008217 9.46 GNB3 CALCA
5 phospholipase C-activating G protein-coupled receptor signaling pathway GO:0007200 9.43 VIP HCRTR2
6 regulation of cytosolic calcium ion concentration GO:0051480 9.37 HCRTR2 CALCA
7 G protein-coupled receptor signaling pathway GO:0007186 9.35 VIP PNOC HCRTR2 GNB3 CALCA
8 feeding behavior GO:0007631 9.26 HCRTR2 CALCA
9 positive regulation of blood vessel diameter GO:0097755 9.16 VIP CALCA
10 neuropeptide signaling pathway GO:0007218 8.8 PNOC HCRTR2 CALCA

Molecular functions related to Cluster Headache according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 neuropeptide hormone activity GO:0005184 8.62 VIP PNOC

Sources for Cluster Headache

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
20 GARD
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
53 NINDS
54 Novoseek
56 OMIM via Orphanet
57 OMIM® (Updated 20-May-2021)
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 Tocris
70 UMLS
71 UMLS via Orphanet
Content
Loading form....